tiprankstipranks
Advertisement
Advertisement
Alterity Therapeutics initiated with a Speculative Buy at Canaccord
PremiumThe FlyAlterity Therapeutics initiated with a Speculative Buy at Canaccord
3M ago
Alterity ‘never lost sight’ of interest in Parkinson’s disease, CEO says
Premium
The Fly
Alterity ‘never lost sight’ of interest in Parkinson’s disease, CEO says
4M ago
Alterity CEO says to meet with FDA, move forward with Phase 3 study
Premium
The Fly
Alterity CEO says to meet with FDA, move forward with Phase 3 study
4M ago
Alterity Therapeutics reports cash balance of A$54.46M as of September 30
PremiumThe FlyAlterity Therapeutics reports cash balance of A$54.46M as of September 30
5M ago
Alterity Therapeutics Reports Change in Substantial Holding by Regal Funds
Premium
Company Announcements
Alterity Therapeutics Reports Change in Substantial Holding by Regal Funds
5M ago
Promising Phase 2 Results for ATH434 Boost Alterity Therapeutics’ Buy Rating
Premium
Ratings
Promising Phase 2 Results for ATH434 Boost Alterity Therapeutics’ Buy Rating
5M ago
Alterity Therapeutics raises A$20M in strategic placement
PremiumThe FlyAlterity Therapeutics raises A$20M in strategic placement
7M ago
Alterity Therapeutics Initiates Trading Halt for Capital Raising Announcement
Premium
Company Announcements
Alterity Therapeutics Initiates Trading Halt for Capital Raising Announcement
7M ago
Alterity Therapeutics Initiates Trading Halt for Capital Raising
Premium
Company Announcements
Alterity Therapeutics Initiates Trading Halt for Capital Raising
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100